151 results about "Ischemic vascular dementia" patented technology

Novel compounds such as DHMP maintain DHM features and pharmacological activities with increased potency and efficacy, improved water solubility, enhanced bioavailability, increased permeability to the blood brain barrier (BBB), and increased stability. Because DHMP retains the therapeutic activities of DHM and has properties that improve its bioavailability, it can be used as a therapeutic agent for treating Alzheimer's disease-related diseases (ADRD) including Alzheimer's disease (AD), Vascular Dementia, Frontotemporal Dementia (FTD), Mixed Dementia as well as neurodegeneration such as Parkinson's disease. Administration of these compounds result in beneficial pathological changes including reduction of Aꞵ and Tau, improvement of neuroinflammation, reduction of cognitive / memory deficits, as well as improvement of anxiety, depression, and aggression. The disclosed DHM derivatives can also be used to treat sleep disorders, neurological disorders such as PTSD, Autism, Epilepsy / Seizures, and Alcohol Use Disorders (AUD), fetal alcohol syndrome (FAD), substance addictions, and cancers.

The BAG3 proteins are useful in the treatment of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Lewy body disease, vascular dementia, mixed dementia and traumatic brain injury, such as chronic traumatic encephalopathy (CTE). A therapeutic BAG3 composition, use of BAG3, and a method of treatment of BAG3 are described.

The present invention includes compositions and methods of treating CNS-related conditions, comprising: administering an effective amount of a compound that lowers the levels of one or more branched-chain amino acids (BCAAs) or metabolites thereof, or any pharmaceutically acceptable salt thereof, wherein the CNS-related conditions is selected from the group consisting of Alzheimer's disease and any related forms of dementia including vascular dementia, Lewy body dementia, frontotemporal dementia, Creutzfeldt-Jacob disease, Wernicke-Korsakoff disease, and Huntington's disease, Multiple sclerosis, Parkinson's disease, autism, Amyotrophic lateral sclerosis (ALS), Hereditary diffuse leukoencephalopathy with spheroids (HDLS) and epilepsy.

A Maclura pubescens extract or fraction or a Prunus cerasoides extract or fraction having neuroglobin (Ngb) activation and neuroprotective effects and, on the basis thereof, a neuroprotective composition containing, as an active ingredient, a Maclura pubescens extract or fraction or a Prunus cerasoides extract or fraction. The neuroprotective composition can be used, through the activation of neuroglobin (Ngb), as a pharmaceutical composition or a food composition for treatment, alleviation and prevention of a stroke, a cerebral infarction, thrombosis, cerebral degenerative disease, vascular dementia, memory loss, short-term memory impairment, a concentration disorder, anxiety, nervousness and the like, and for brain damage protection, brain function improvement and cranial nerve cell protection.

The invention relates to the field of medicine raw material extraction. The invention discloses a drug raw material extraction device for preventing and treating vascular dementia and a use method, and aims to solve the problem that the juice residual rate in drug raw materials is relatively high due to only one-time extrusion when the drug raw materials are extruded by a raw material extraction device. The device is composed of a crushing mechanism, an extruding and discharging mechanism and a secondary extruding mechanism. According to the medicine raw material extraction device for preventing and treating vascular dementia and the using method, a motor runs to drive a sliding block to slide in an annular wave limiting channel between two wave ring sleeves, so that a vertical plate is driven to reciprocate up and down, and two parallel plates are matched to push a pushing plate to slide in a containing groove in a reciprocating manner; the raw materials in the containing groove are extruded, liquid in the raw materials is extruded out, the liquid enters the collecting barrel through filtering of the filtering barrel, the raw materials in the containing groove are continuously and transversely extruded, and continuous operation of the device is guaranteed.

The invention provides an alpha, beta-unsaturated amide compound as well as a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound as shown in the following formula I. The definition of each group is described in the specification. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and cerebral apoplexy. # imgabs0 #

Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represented by formula I, wherein the definition of each group is as described in the description. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and strokes.

The invention discloses a 2-(piperidinyl) pyridazinone compound (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-(piperidinyl) pyridazinone compound, a pharmaceutical composition of the 2-(piperidinyl) pyridazinone compound and application of the 2-(piperidinyl) pyridazinone compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary diseases, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension, Alzheimer disease, vascular dementia, glaucoma, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, ischemic optic neuropathy or chronic kidney disease. The present invention relates to a compound of the formula [I], the formula [II] or the formula [III], or a pharmaceutically acceptable salt thereof:wherein each symbol is as defined in the DESCRIPTION.

The preparation method comprises the following steps: detecting the concentration of cytoplasmic acyl-coenzyme A thioester hydrolase in a sample by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) method, and carrying out regression analysis through Logistic, the correlation between the serum level of the cytoplasm acyl-coenzyme A thioester hydrolase in an AD (Alzheimer's disease) patient and a vascular dementia (VD) patient and the cognitive impairment degree and the A beta 40 content is evaluated, and whether the expression of the cytoplasm acyl-coenzyme A thioester hydrolase is closely related to the AD progress or not is judged. An effective molecular marker is provided for differential diagnosis of an AD patient and a VD patient, a large number of tests prove that the cytoplasm acyl-coenzyme A thioester hydrolase is highly expressed in the AD patient, the cytoplasm acyl-coenzyme A thioester hydrolase serving as an AD serum molecular marker has high diagnostic value, and when the serum content of the cytoplasm acyl-coenzyme A thioester hydrolase is higher than 62.5 pg / ml, the cytoplasm acyl-coenzyme A thioester hydrolase can assist AD diagnosis and can also serve as an auxiliary index for distinguishing AD and VD. The kit is applied to preparation of a kit for differential diagnosis of AD and VD.

This invention discloses a compound preparation for treating vascular dementia and its preparation method. The active pharmaceutical ingredient consists of protopanaxadiol and gallic acid in a 1:1 mass ratio, and the dosage form is liposomes. The preparation method includes extraction, mixing, liposome preparation, and optional freeze-drying steps: protopanaxadiol and gallic acid are extracted and purified from ginseng rhizome and Terminalia chebula fruit, respectively. After mixing, they are combined with phospholipids and cholesterol to prepare a lipid membrane. The membrane is then homogenized by hydration, low-temperature ultrasound, and high-pressure microfluidic jet to obtain a homogeneous liposome suspension, which can be further freeze-dried into a freeze-dried powder. The 1:1 composition of protopanaxadiol and gallic acid targets multiple points on the pathological mechanism of vascular dementia, showing significant therapeutic effects and broad application prospects. This preparation uses a liposome dosage form to improve the bioavailability of the active ingredient, the preparation process parameters are controllable, the active ingredient has high purity, the liposomes have uniform particle size, high encapsulation efficiency, and good stability.

The present disclosure provides an extended-release gel formulation containing a biocompatible polymer and an angiotensin-(1-7) oligopeptide or a variant thereof. Also provided are methods of treating subjects with vascular dementia, e.g., using the formulations disclosed herein or compositions containing the same, a subject can be administered the extended-release gel formulation to treat the vascular dementia.

The invention belongs to the technical field of medicinal chemistry, and relates to a benzazepine compound or pharmaceutically acceptable salt thereof as well as a preparation method and application of the benzazepine compound, in particular to a compound with a structural general formula as shown in a formula (I). The benzoazepine compound disclosed by the invention has a remarkable curative effect on treating brain organic lesion diseases, including vascular lesion and degenerative lesion, especially vascular dementia, Alzheimer's disease and cholinergic deficiency related diseases. Formula (I).

The present invention relates to a class of monoclonal antibodies having anti–von Willebrand factor (VWF) effects, and a use thereof. A pharmaceutical composition of the monoclonal antibodies or antigen-binding fragments having anti–von Willebrand factor effects provided by the present invention can be used to reduce VWF levels in the body, thereby preventing and treating thrombotic microangiopathies having various causes (including thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, and atypical hemolytic-uremic syndrome), cardiovascular disease, stroke, atherosclerosis, senile dementia, vascular dementia, and bacterial and viral infectious diseases.

Association comprising: dry extract of Bacopa monnieri, Astaxanthin, Vitamin E, L-theanine and dry extract of Centella asiatica for use as an adjuvant in the prevention of vascular dementia, as it is able to reduce the main modifiable risk factors of cognitive vascular impairment (VCI).

The invention discloses ursodesoxycholic acid and amino acid conjugates (I), pharmaceutically acceptable salts thereof, a preparation method of the ursodesoxycholic acid and amino acid conjugates, a pharmaceutical composition of the ursodesoxycholic acid and amino acid conjugates and application of the ursodesoxycholic acid and amino acid conjugates in preparation of drugs for treating and / or preventing comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

To provide an effective agent for diabetic dementia and vascular dementia.SOLUTION: This invention provides an agent comprising a RGMa inhibiting substance for preventing or treating dementia selected from diabetic dementia and vascular dementia.SELECTED DRAWING: Figure 1

The invention discloses an aminoamide alkyl thioester compound (I), pharmaceutically acceptable salts thereof, a preparation method of the aminoamide alkyl thioester compound, a pharmaceutical composition of the aminoamide alkyl thioester compound and application of the aminoamide alkyl thioester compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The invention discloses an amide alkyl thiol ester compound (I) as well as a preparation method and a pharmaceutical composition thereof, and application of the amide alkyl thiol ester compound in preparation of drugs for treating and / or preventing diseases by resisting oxidative stress, inhibiting amyloid protein aggregation and resisting neuroinflammation. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The present application relates to the use of vascular BACE1 as a therapeutic target for diseases related to cerebral small vessel injury. Specifically, it relates to the use of a substance that reduces the expression level of the beta-secretase (BACE1) gene and / or an inhibitor of the enzymatic activity of BACE1 protein in the preparation of a drug for treating or alleviating cerebrovascular disease, wherein the disease related to cerebral small vessel injury is preferably Alzheimer's disease, amyloid cerebral small vessel disease, and vascular dementia. The inventors have found that an increase in the content of BACE1 can cleave the tight junction protein Occludin, resulting in the degradation and loss of tight junction proteins between vascular endothelial cells, causing the structure and function of the blood-brain barrier to be damaged, ultimately leading to cerebral microbleeds and cognitive dysfunction and other pathological phenotypes of diseases related to cerebral small vessel injury; inhibition of the enzymatic activity of BACE1 can improve these pathological phenotypes of diseases related to cerebral small vessel injury.

The present disclosure provides an extended-release gel formulation containing a biocompatible polymer and an angiotensin-(1-7) oligopeptide or a variant thereof. Also provided are methods of treating subjects with vascular dementia, e.g., using the formulations disclosed herein or compositions containing the same, a subject can be administered the extended-release gel formulation to treat the vascular dementia.

The invention concerns a compound of formula (I) (I) R1═H, —CH3 or acyl group, preferably R1═—CH3R2═H or halogen atom selected in the group consisting of: F, Cl, Br, I, preferably R2═H or a pharmaceutically acceptable isomer, salt and / or solvate thereof, for use in preventing and / or treating neurodegenerative diseases when central muscarinic neurotransmission is compromised, wherein said neurodegenerative disease is selected in the group consisting of Alzheimer's Disease (AD), vascular dementia, Dementia with Lewy bodies (DLB), mixed dementia, frontotemporal lobar degeneration (FTLD), and Parkinson's disease (PD).

The invention discloses application of steroid saponin of trillium tschonoskii maxim to preparation of a medicine for treating vascular dementia, and relates to the technical field of medicines. Animal experiments prove that the berberis apiacea steroid saponin can improve the spatial reference learning function of cerebral ischemia rats, improve the spatial reference memory function of the cerebral ischemia rats and enhance the long-term memory function of the cerebral ischemia rats. In addition, brain tissue damage and white matter structure damage of rats suffering from cerebral ischemia can be relieved, axonal myelin sheath microstructure reconstruction and white matter fiber reconstruction of the rats suffering from cerebral ischemia are promoted, and myelin sheath regeneration of rats suffering from vascular dementia is promoted. Network pharmacological analysis finds that the age grass total steroid saponin has a wide regulation effect on OPCs and OLs cell components and molecular functions, and further, OPCs differentiation myelin sheath inhibition related factors are regulated and controlled, and white matter myelin sheath regeneration is promoted.

The present invention relates to a C-17 carbonyl-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C-17 carbonyl-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2 activator, and preparation of a medicament for treating / preventing diseases. The diseases comprise cerebral small vascular disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, schizophrenic cognitive impairment, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc., or other disease states and conditions which are obvious to a person skilled in the art. Also provided are a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a pharmaceutical composition containing same.

The invention provides application of a salidroside derivative in preparation of a medicine for preventing and / or treating cognitive impairment caused by cerebrovascular lesion, and belongs to the technical field of biological medicine. The invention discloses application of a salidroside derivative SHPL-49 in preparation of a medicine for preventing and / or treating cognitive impairment caused by cerebrovascular lesion. The SHPL-49 can effectively improve the learning and memory functions after brain injury, recover the exercise coordination ability, relieve corpus callosum region myelin sheath loss above the hippocampus region and further protect the brain-sea horse region synapses. The SHPL-49 has the efficacy of treating the vascular cognitive impairment and the vascular dementia. According to the application, the medical application of the SHPL-49 is widened, and a new way is provided for treating cognitive impairment diseases caused by cerebrovascular lesion.

This invention discloses the application of total small molecules of Polygonatum cyrtonema in the preparation of drugs for treating vascular dementia, belonging to the field of natural medicine technology. This invention obtains total small molecules of Polygonatum cyrtonema through a combination of water extraction and alcohol precipitation with macroporous adsorption resin purification. Experiments using a rat model of vascular dementia showed that these total small molecules of Polygonatum cyrtonema effectively improved the degree of neurological function impairment and learning and memory abilities in rats, indicating that the total small molecules of Polygonatum cyrtonema prepared by this invention can effectively treat vascular dementia, providing a new drug source and treatment method for clinical vascular dementia treatment.

The present invention provides a prophylactic or therapeutic agent for dementia selected from the group consisting of diabetic dementia and vascular dementia, the prophylactic or therapeutic agent comprising an RGMa inhibitor.

This invention provides an agent comprising a RGMa inhibiting substance for preventing or treating dementia selected from diabetic dementia and vascular dementia.

The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention relates to the technical field of drug dose screening, in particular to a method for screening the optimal dose of metformin for treating vascular dementia by using an OGD / R-SHSY5Y cell model, which comprises the following steps: constructing the OGD / R-SHSY5Y cell model to simulate the pathological state of vascular dementia; setting a control group, an OGD / R model group and a metformin treatment group with different concentrations, and additionally arranging a pathway inhibitor verification group; the cell proliferation activity is detected through a CCK8 method, the cell apoptosis rate is detected through an Annexin-V-FITC / PI double staining method, expression of apoptosis-related genes and key genes is detected through a qPCR method and a Western blot method, and the inflammatory factor level is detected through an ELISA method. By integrating multi-dimensional detection results, the optimal dosage of the metformin, which not only can significantly improve cell viability and inhibit cell apoptosis, but also can effectively regulate and control key gene expression and inflammatory factor balance, is screened out. Through multi-index collaborative detection and pathway mechanism verification, accurate screening of the optimal dose of the metformin for treating vascular dementia is realized.